FUSHILAI Obtains EDQM CEP Certification for Alpha Lipoic Acid Powder API
February 13, 2025 Regulatory Announcement
Quality Certification Achieved
FUSHILAI has received the European Pharmacopoeia Certificate of Suitability (CEP No. 2023-359-Rev 00) from the European Directorate for the Quality of Medicines (EDQM) for its production of Alpha Lipoic Acid Powder active pharmaceutical ingredient (API). The certification is valid for five years from February 3, 2025.
Therapeutic Profile
- Originally developed by STADA Arzneimittel AG (Germany)
- Primary application: Treatment of diabetic polyneuropathy
- Potent antioxidant properties
- Metabolic syndrome management
Certified Alpha Lipoic Acid Powder Specifications
Quality Parameters
- ▸ CEP Certification: 2023-359-Rev 00
- ▸ Purity: ≥99.5% (HPLC)
- ▸ Particle Size: 80-120 Mesh
- ▸ CAS Number: 1077-28-7
- ▸ Storage: 2-8°C in airtight containers
Where to buy bulk Alpha Lipoic Acid powder supplier? As a professional supplier for pharmaceutical ingredients and nutritional compounds, we offer:
- GMP-certified production
- Custom particle size optimization
- Regulatory documentation support
- Global logistics solutions